Research Groups and R&D Platforms: Assay development
Research Group:
Gas and biosensors
Jouko Peltonen
jouko.peltonen[at]abo.fi
Laboratory of physical chemistry,
Åbo Akademi University
Antibacterial, Antibodies, Assay development, Atomic-force microscopy, Diagnostics, Electron microscopy, Formulation, In Vitro Diagnostics, Inflammation, Molecular diagnostics, Nanoparticles, Organic compounds, Particle size analysis, Personalized medicine, Pharmacy, Physico-chemical properties, Point of care, Porosity, Surface area, Zeta potential
Research Group:
New methods and biomarkers for IBD
Harri Siitari
harri.siitari[at]utu.fi
Laboratory of Medical physics,
University of Turku
Biomarkers and decision support tools for personalized diagnostics and care
Assay development, Autoimmune diseases, Biomarker, Biomedicine, Biotechnology, Data mining, Diagnostics, In Vitro Diagnostics, Inflammation, Molecular diagnostics, Neurological disorders, NMR, Personalized medicine
Research Group:
High Content Screening Laboratory
Matthias Nees (Principal Investigator)
Malin Åkerfelt (Contact person, in picture)
malake[at]utu.fi
Institute of Biomedicine,
Univesity of Turku
Assay development, Bioinformatics, Biomedicine, Biotechnology, Breast cancer, Cancer, Disease models, Drug target, High throughput imaging, Hit to lead, Imaging, Inflammation, Lead optimization, Lung cancer, Machine learning, Molecular Cell Biology, Natural Compounds, Prostate cancer, Screening, Target discovery
Research Group:
Laboratory of Biophysics
Pekka Hänninen
pekka.e.hanninen[at]utu.fi
Institute of Biomedicine,
University of Turku
Assay development, Atomic-force microscopy, Biomolecular chemistry, Cancer, Data mining, Diabetes, Diagnostics, Fluorescence spectroscopy, Imaging, In Vitro Diagnostics, Machine learning, Nanoparticles, Physics, Super-resolution imaging
Research Group:
Innate and adaptive immunity in viral infections
Ilkka Julkunen
ilkka.julkunen[at]utu.fi
Institute of Biomedicine
University of Turku
Antibodies, Assay development, Autoimmune diseases, Basic research, Biomarker, Biomedicine, Biotechnology, Diagnostics, Imaging, Imaging software, Immunology, In Vitro Diagnostics, Infection, Inflammation, Medicinal chemistry, Molecular Biology, Molecular Cell Biology, Molecular diagnostics, Molecular modelling, Neurological disorders, Pattern recognition, Proteomics, Receptor, Signaling, Virology
R&D Platform:
Screening Unit
The screening unit offers academic researchers and industrial customers a broad range of services for identifying and optimising bioactive molecules for the drug discovery process. These include molecular modelling and in silico screening, development of screening assays and compound library screens, in vitro and in situ hit validation, hit optimisation and SAR analyses. A suite of cell and tissue-based disease models for oncology and neurological diseases are available for further validation of optimised hits or for independent phenotypic screens. High-throughput kinetic assays of changes in morphology or intracellular signalling over time may be integrated into chemical, genetic or optogenetic perturbation screens. A library of reporters in gene-delivery vectors are available for this purpose. The unit also has experience performing screens and toxicological evaluations in small animal models.
Contact details
High-throughput screens, screen-compatible assays, high-throughput microscopy, libraries, optogenetics, cell-based neurological disease models:
michael.courtney[at]utu.fi
3D oncology models, phenotypic screens, high-content screens:
malin.akerfelt[at]utu.fi
Medicinal chemistry, virtual screening and molecular modelling:
olli.pentikainen[at]utu.fi
Assay development, Basic research, Disease models, High throughput imaging, Hit to lead, Lead optimization, Medicinal chemistry, Molecular modelling, R&D Platforms, Screening, Signaling, Target discovery
